构建一个基于金属有机框架的长效序列释放系统,用于治疗阿尔茨海默氏症
Qi Ding1, Yun Zhao1, Enpeng Xi1
1Key Laboratory of Polyoxometalate and Reticular Material Chemistry of Ministry of Education and Faculty of Chemistry, Northeast Normal University, Changchun, 130024, China.
Advanced healthcare materials
|December 3, 2024
概括
这项研究引入了一种用于阿尔茨海默病 (AD) 治疗的新型药物载体,利用Mn-MOF-74连续提供抗氧化剂,以扩大大脑保护和改善记忆功能.
科学领域:
- 材料科学 材料科学 材料科学
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 阿尔茨海默病 (AD) 的发病原因尚不清楚,因此需要终身服药,这对严重记忆障碍患者来说是个挑战.
- 传统的药物载体缺乏与药物分子的相互作用,限制长效和顺序释放,以有效管理AD.
研究的目的:
- 开发一种用于阿尔茨海默氏症 (AD) 的新型药物递送系统,具有序列和长效抗氧化剂释放.
- 在小鼠模型中评估开发的载体在维持大脑氧化平衡和改善认知缺陷方面的有效性.
主要方法:
- 由于结构相似性和不同的吸附能量,利用Mn-MOF-74作为二甲 (DHQ) 和复星 (Res) 的载体.
- 在实验室中研究了连续的药物释放动力学和抗氧化剂疗效,将其与维生素E进行比较.
- 在5×FAD转基因小鼠中评估DR@MOF配方的治疗潜力,评估大脑氧化平衡和空间学习/记忆.
主要成果:
- 装载DHQ和Res的Mn-MOF-74 (DR@MOF) 表明药物释放顺序,DHQ的释放速度快于Res.
- DR@MOF提供了持续的抗氧化作用大约72小时,比维生素E要长得多.
- 在5×FAD小鼠中,DR@MOF有效地维持了大脑的氧化平衡,改善了空间学习和记忆缺陷.
结论:
- 该DR@MOF系统为阿尔茨海默病的长效和顺序治疗提供了一个有希望的策略.
- 这种新型的载体系统有可能通过增强药物输送和在大脑中持续的抗氧化作用来改善AD患者的治疗结果.
更多相关视频
10:19Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps
Published on: August 14, 2016
9.2K
06:44Quantitative Analysis of Mitochondria-Associated Endoplasmic Reticulum Membrane (MAM) Stabilization in a Neural Model of Alzheimer's Disease (AD)
Published on: January 10, 2025
428
相关概念视频
Alzheimer's Disease: Treatment
163
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
163
Alzheimer's Disease: Overview
447
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
447
